Mainstay of Treatment for Myeloma, Dexamethasone, Shows Very Significant Survival Benefit for COVID-19 Patients

Published Jun 16, 2020

Mainstay of Treatment for Myeloma, Dexamethasone, Shows Very Significant Survival Benefit for COVID-19 Patients

NOW
PLAYING
Houston Coronavirus Crisis -- MD Anderson Taking in COVID-19 Cases-- What Cancer Patients Can Do
NOW
PLAYING
Ovarian Cancer Treatment for Frail Patients
NOW
PLAYING
Chemotherapy Side Effects and Fatigue
NOW
PLAYING
New Hope For Esophageal Cancer Patients -- Immunotherapy Opdivo Approved For Treatment Of Advanced Esophageal Cancer
NOW
PLAYING
Which Triple-Drug Regimen is a Better Frontline Treatment for Multiple Myeloma?
NOW
PLAYING
Options For Ovarian Cancer Maintenance Therapy: PARP Inhibitors & Avastin
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.